News | Publications | Posters | Upcoming Events |
-
September 25, 2020
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives -
September 16, 2020
PsychoGenics Drug Discovery Featured in Nature Biopharma Dealmakers -
July 28, 2020
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration -
November 6, 2019
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP) -
November 4, 2019
PsychoGenics Appoints Mark A. Varney, PhD as Chief Scientific Officer -
October 30, 2019
PsychoGenics Announces Milestones Associated with Sunovion’s Advancing Pipeline -
September 27, 2019
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia -
May 10, 2019
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia -
December 13, 2018
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia